XRHealth Acquires Swing Therapeutics to Create Largest Extended Reality Chronic Pain Platform
AI-summarised brief · reviewed before publication
XRHealth has formally acquired Swing Therapeutics, establishing the largest multi-device extended reality digital health platform for chronic conditions. The transaction incorporates Swing’s flagship Stanza program, the first FDA De Novo–authorized prescription digital behavioral therapeutic for fibromyalgia symptoms affecting 10 million Americans. Validated by a Phase 3 randomized controlled trial published in The Lancet, Stanza utilizes Acceptance and Commitment Therapy to reduce pain, fatigue, and depression. The deal also integrates Swing Care, a virtual specialty clinic led by Dr. Andrea Chadwick, combining behavioral software with physician-monitored medication management. Operating on a fully covered model, the combined infrastructure deploys across VR glasses, smartphones, and wearables. It delivers continuous, personalized whole-patient care reimbursed via Medicare Part B, VA programs, and commercial insurance, shifting focus from consumer widgets to clinically validated, software-driven interventions.
💡 Why It Matters
- · The acquisition validates a reimbursement-ready model for digital therapeutics, proving that immersive technology can generate sustainable revenue through established insurance pathways.
- · By merging FDA-authorized software with active physician oversight, the platform transforms chronic pain management from passive self-care into a billable, clinically integrated medical service.